EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Streamlining Inherited Cancer Identification via an EMR-Integrated Risk Assessment Platform

Lori A Orlando, Kathleen F Mittendorf, Nathan A Bihlmeyer, Harris T Bland, Rachel A Myers, Siddharth Pratap, Natasha Celaya-Cobbs, Justin Andujar, Meredith Gerhart, Azita Sadeghpour, Gillian Hooker, R Ryanne Wu und 8 weitere

JAMA Network Open · 29.04.2026 · 9 (4) · e269816

DOI: 10.1001/jamanetworkopen.2026.9816 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JAMA Network Open, online erschienen am 29.04.2026. Verfasst von Lori A Orlando und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina. Hauptthemen laut MEDLINE: Electronic Health Records, Medical History Taking, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Approximately 10% of cancers are attributable to heritable germline variants, yet identification of individuals at risk remains suboptimal.

Objective

To assess the feasibility of personal history and family health history (FHH) risk assessment technology via the electronic medical record (EMR) to enhance identification of patients at risk for a broad array of inherited cancer syndromes. Design, Setting, and Participants This single-arm, nonrandomized clinical trial was completed from October 1, 2021, to September 1, 2023, with no follow-up period in unselected patients receiving care at Vanderbilt University Medical Center. Adult patients (aged ≥18 years) were invited through their EMR patient portals to complete an eligibility survey. Eligible participants completed the survey, were English speaking, and had no prior genetic counseling. The data analysis was performed between August 15 and November 7, 2025.

Intervention

Electronic medical record–integrated risk assessment platform that collected self-reported personal history and FHH to assess risk for 24 hereditary cancer syndromes. Main Outcomes and Measures The primary outcome was the completion rate of the risk assessment platform. Secondary outcomes included the percentage of newly identified participants meeting guideline criteria for genetic counseling and whether previsit FHH collection increased genetic counseling capacity by decreasing time spent in counseling.

Results

A total of 1685 patients were consented to participate (mean [SD] age, 55.4 [15.1] years; 1217 female [72.2%]; 95 of Black or African American [5.6%] 1405 of White [83.4%], and 181 of other [multiracial, other, or unknown] [10.6%] race; 38 of Hispanic or Latino [2.3%], 1388 of non-Hispanic or Latino [82.4%], and 111 of unknown [6.6%] ethnicity). Among participants consented, 1483 (88.0%) were provided access to the risk assessment, 1106 (74.6%) started the assessment, 636 (57.5%) completed it, and 544 (49.1%) received a risk report. Younger age and unknown race and ethnicity were the only significant variables associated with completion (mean [SD] age, 53.5 [15.3] vs 56.9 [14.8] years for completers vs noncompleters, respectively; unknown race, 77 [14.2%] vs 43 [7.6%] for noncompleters; unknown ethnicity, 49 [9.0%] vs 20 [3.6%] for completers vs noncompleters, respectively). Among participants who completed the risk assessment, 155 (28.5%) met guideline criteria for genetic counseling, yet 74 (47.7%) were previously identified as at risk by billing codes. A total of 31 participants (20.0%) eligible for genetic counseling attended. Manual outreach efforts and counseling duration did not differ between risk assessment–assisted and usual care visits. Conclusions and Relevance In this nonrandomized clinical trial, almost one-third of the population met national genetic counseling criteria for an inherited cancer syndrome, highlighting a substantial gap in usual care identification. Integrating patient-facing FHH collection and assessment tools for primary care patients improves inherited cancer risk identification and highlights opportunities to further enhance both risk assessment processes and genetic counseling attendance. Trial Registration ClinicalTrials.gov Identifier: NCT05079334

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Electronic Health RecordsMedical History TakingNeoplastic Syndromes, HereditaryHumansFemaleMiddle AgedRisk AssessmentAdultMaleGenetic CounselingAgedGenetic Predisposition to DiseaseGenetic Testing

Autor:innen und Institutionen

  • Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
  • Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Medicine Clinical Research Unit, Duke University School of Medicine, Durham, North Carolina.
  • Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, Tennessee.

Förderung

  • NCI NIH HHS

Zitieren

APA

Orlando, L. A., Mittendorf, K. F., Bihlmeyer, N. A., Bland, H. T., Myers, R. A., Pratap, S., Celaya-Cobbs, N., Andujar, J., Gerhart, M., Sadeghpour, A., Hooker, G., Wu, R. R., Marshall, D. R., Edwards, C., Frederickson, K. L., Leegon, J., Jones, S. H., Rosenbloom, S. T., Peterson, J. F., & Wiesner, G. L. (2026). Streamlining Inherited Cancer Identification via an EMR-Integrated Risk Assessment Platform. JAMA Network Open, 9(4), e269816. https://doi.org/10.1001/jamanetworkopen.2026.9816

Vancouver

Orlando LA, Mittendorf KF, Bihlmeyer NA, Bland HT, Myers RA, Pratap S, et al. Streamlining Inherited Cancer Identification via an EMR-Integrated Risk Assessment Platform. JAMA Network Open. 2026;9(4):e269816. doi:10.1001/jamanetworkopen.2026.9816

BibTeX
@article{Orlando2026,
  author = {Orlando, Lori A and Mittendorf, Kathleen F and Bihlmeyer, Nathan A and Bland, Harris T and Myers, Rachel A and Pratap, Siddharth and Celaya-Cobbs, Natasha and Andujar, Justin and Gerhart, Meredith and Sadeghpour, Azita and Hooker, Gillian and Wu, R Ryanne and Marshall, Dana R and Edwards, Clasherrol and Frederickson, Katie L and Leegon, Jeff and Jones, Sarah H and Rosenbloom, S Trent and Peterson, Josh F and Wiesner, Georgia L},
  title = {Streamlining Inherited Cancer Identification via an EMR-Integrated Risk Assessment Platform},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {4},
  pages = {e269816},
  doi = {10.1001/jamanetworkopen.2026.9816}
}
Kostenlos starten →